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PURPOSE. We investigated relationship of glaucoma with measurements related to auto-
nomic dysfunction, including heart rate variability (HRV) and blood pressure (BP).
METHODS. Glaucoma was defined using a questionnaire-based algorithm for 86,841 Life-
Lines Cohort Study participants. Baseline HRV (root mean square of successive differ-
ences [RMSSD]) was calculated from resting electrocardiograms; systolic BP (SBP), dias-
tolic BP (DBP), mean arterial pressure (MAP), and pulse pressure (PP) were oscillometric-
based measurements. We used a generalized linear mixed model, adjusted for age, age
square, sex, body mass index, and familial relationships to assess the relationship of
baseline HRV and BP (continuous and quartiles), hypertension, and antihypertensive
medication with glaucoma at follow up (median, 3.8 years).
RESULTS. The odds ratio (OR) of glaucoma was 0.95 (95% confidence interval [CI], 0.92–
0.99) per unit increase in log-transformed RMSSD (in ms), indicating that autonomous
dysfunction (low HRV) is associated with a higher risk of glaucoma. Per 10-mm Hg
increase in BP, we found ORs of 1.03 (95% CI, 1.01–1.05; P = 0.015) for SBP, 1.01 (95% CI,
0.97–1.05; P = 0.55) for DBP, 1.03 (95% CI, 1.00–1.06; P = 0.083) for MAP, and 1.04 (95%
CI, 1.01–1.07; P = 0.006) for PP. The OR for the lowest versus highest RMSSD quartile was
1.15 (95% CI, 1.05–1.27; P = 0.003). The ORs for the highest versus second quartile were
1.09 (95% CI, 0.99–1.19; P = 0.091) for SBP and 1.13 (95% CI, 1.02–1.24; P = 0.015) for
PP. Glaucoma was more common among hypertensives (OR, 1.25; 95% CI, 1.16–1.35; P
< 0.001); among those using angiotensin-converting enzyme (ACE) inhibitors (OR, 1.35;
95% CI, 1.18–1.55; P < 0.001); and among those using calcium-channel blockers (OR,
1.19; 95% CI, 1.01–1.40; P = 0.039).
CONCLUSIONS. Low HRV, high SBP, high PP, and hypertension were associated with glau-
coma. Longitudinal studies may elucidate if autonomic dysregulation and high BP also
predict glaucoma incidence.
Keywords: glaucoma, blood pressure, autonomic dysfunction, heart rate variability,
hypertension, antihypertensive medication
Glaucoma is a group of complex ocular diseases accom-panied by progressive damage to the optic nerve.
Primary open-angle glaucoma (POAG) is the most common
subtype in the Western world and Africa. Mechanical,1,2
vascular,3,4 genetic,5–7 and, recently, autonomic nervous
function8 theories have been proposed to explain the mech-
anisms behind glaucoma. The mechanical theory refers to
axonal damage of the optic nerve that is directly related to
an elevated intraocular pressure (IOP), the most important
risk factor for glaucoma, or possibly to an elevated pres-
sure difference across the lamina cribrosa (IOP vs. intracra-
nial pressure). The vascular theory proposes ischemia due
to insufficient blood supply to the optic nerve head as a
possible mechanism for optic nerve damage.9 This has been
linked to autonomic dysfunction, hypertension (HTN), and
low blood pressure (BP). Current results are conflicting and,
partially due to that, controversial.
By evaluating 24-hour BP measurements, prior studies
suggest that nocturnal hypotension may be a contribut-
ing factor for anterior ischemic optic neuropathy and
glaucoma.10,11 However, abnormalities in ocular blood
flow occur at both high12,13 and low14 BP in glau-
coma, yielding a J- or U-shaped15 relationship between
BP and glaucoma. This apparent controversy has led to
a new hypothesis, the involvement of autonomic nervous
dysfunction. Studies speculate that autonomic dysfunc-
tion affects the susceptibility of the optic nerve to BP
changes and is most prominent in normal-tension glau-
coma (NTG), a glaucoma subtype where the most impor-
tant risk factor, an elevated IOP, is lacking.16,17 Auto-
nomic dysfunction involvement in glaucoma pathogen-
esis is further supported by a cold provocation test,
where glaucomatous individuals had greater sympathetic
innervation.17
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Compared to normal subjects, glaucoma patients exhibit
blood flow abnormalities in vessels of the optic nerve head,18
retina,18 retrobulbar tissue,19 and choroid.18,20,21 With limited
information regarding autonomic dysfunction involvement,
several researchers proposed that ocular vessel disturbances
are linked to plasma levels of endothelin-1,22 systemic blood
pressure,23,24 and vasospasm.25 Autonomic function reflects
the effect of parasympathetic nervous system activity on the
heart. Autoregulation is a related mechanism found in the
nervous system that aims to maintain a stable blood flow
despite changes in blood pressure, including changes in
intraocular pressure.16,19
There is a paucity of reports investigating the role of auto-
nomic dysfunction in glaucoma. Dysfunctional autonomic
control was reported to lead to an unstable blood supply,
related to a reduced perfusion pressure in glaucomatous
eyes.17,26,27 In fact, a low heart rate variability (HRV) was
associated with a faster rate of central visual field loss in
glaucoma.28 HRV is a commonly used proxy measurement
for autonomic modulation of the heart.29
Regarding glaucomatous damage and systemic BP, there
are conflicting reports. The Rotterdam30 and Beaver Dam31
eye studies reported a higher risk of POAG with high BP,
whereas the Barbados Eye Study32 has reported the oppo-
site. Alternatively, two US studies found a U-shaped relation-
ship, suggesting that those with either low or high BP may
be at greater risk for glaucoma.12,15
In this study, we explored associations of HRV and BP
with glaucoma in the LifeLines Cohort Study, which involves
a large cohort from the Northern Netherlands that is repre-
sentative of the general population. We also studied the role
of antihypertensive drugs in the relationship between glau-
coma and BP. We hypothesized that participants with low
HRV values, as well as those with high and low BP measure-
ments, have higher odds of glaucoma.
METHODS
Ethical Approval
The LifeLines data collection was approved by the medical
ethics committee of the University Medical Center Gronin-
gen. Written informed consent was obtained from all partic-
ipants, and the data collection was conducted in accordance
with the tenets of the Declaration of Helsinki.
Study Design and Sample
We used phenotypic data from the LifeLines Cohort Study
and Biobank, a multidisciplinary prospective population-
based cohort study of the Northern Netherlands. The Life-
Lines cohort employs a broad range of investigative proce-
dures to assess the sociodemographic, biomedical, physi-
cal, behavioral, and psychological factors that contribute to
the health and disease of the general population, with a
special focus on multi-morbidity and complex genetics. Life-
Lines participants were asked to invite their family members
(i.e., partners, parents, and children), resulting in the forma-
tion of a three-generation family study. The current study
included 17,379 families, with an average family size of 3.32,
and 29,082 singletons (i.e., no family members included).
A questionnaire on diagnosis and treatment of eye condi-
tions, which included the National Eye Institute Visual Func-
tion Questionnaire-25 (NEI-VFQ-25),33 was administered to
all participants (n = 110,759) 18 years of age and older
during the first follow-up visit between 2014 and 2017, after
a median period of 3.8 years after baseline. Further details
on design and data collection approaches used by LifeLines
are described elsewhere.34,35
Measurement and Definition of Glaucoma
We used a previously described algorithm for defining glau-
coma in LifeLines,36 which was based on self-report of glau-
coma diagnosis and treatment in combination with the NEI-
VFQ-2533 (for details, see Neustaeter et al.36). In short, this
algorithm classifies participants as definite, probable, or
possible glaucoma cases, or as healthy. Definite glaucoma
cases were those who reported incisional surgery for glau-
coma. These cases were also used to define a glaucoma-
specific complaints pattern within the NEI-VFQ-25. Proba-
ble cases were those who self-reported glaucoma (includ-
ing the use of IOP-lowering medication and a history of
glaucoma laser treatment) together with glaucoma-specific
complaints above a certain threshold. Possible cases were
those who either self-reported glaucoma or had glaucoma-
specific complaints. As such, the algorithm includes both
participants who were aware (definite, probable, and possi-
ble glaucoma by self-report) and unaware (possible glau-
coma by complaint) of their disease status. The algorithm
was applied to participants in the first follow-up visit with
available eye questionnaire data. In this study, unless spec-
ified otherwise, the term “glaucoma” refers to the defi-
nite, probable, and possible cases combined. Aiming for
primary glaucoma, the proxy excluded participants with
self-reported macular degeneration or (laser) surgery for
diabetes or retinal detachment. The questionnaire did not
allow for discrimination between open-angle and narrow-
angle glaucoma. Based on the prevalence ratio of open-angle
and narrow-angle glaucoma in the Western world, however,
the majority of cases will have open-angle glaucoma.37,38
Predictor Variables and Covariates
Predictor variables were measured during the baseline visit
from LifeLines. HRV was represented as the log of the root
mean square of successive differences (RMSSD), measured
in milliseconds, which quantifies normal beat-to-beat vari-
ance in heart rate and is used to estimate the vagally medi-
ated modulation of the heart.39 RMSSD was calculated with
a 10-second resting electrocardiogram (ECG) reading (for
details, see Tegegne et al.40 and Munoz et al.41). We previ-
ously demonstrated the validity of RMSSD based on an ultra-
short (10-second) ECG recording as a measure of HRV by
comparing it to the current gold standard recording of 4
to 5 minutes.41,42 For BP, 10 consecutive BP measurements
were obtained in a supine position using an automated
oscillometric method (Dinamap PRO 100V2; GE Healthcare,
Chicago, IL, USA); the last three measurements were aver-
aged to yield systolic BP (SBP), diastolic BP (DBP), and
mean arterial pressure (MAP) values. MAP was provided
by the device; pulse pressure (PP) was calculated as
PP = SBP – DBP.43
High BP was defined as SBP ≥ 140 mm Hg and/or DBP
≥ 90 mm Hg, and HTN as high BP and/or use of antihy-
pertensive medication. The generic names and Anatomical
Therapeutic Chemical (ATC) codes of all common antihyper-
tensive medications were obtained; angiotensin-converting
enzyme (ACE) inhibitors are assigned ATC code C09A,
calcium-channel blockers ATC code C08, diuretics ATC code
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TABLE 1. Population Characteristics and Distribution of HRV and BP Data Stratified by Glaucoma Status
Variables All Cases (n = 3838) Possible Cases Excluded (n = 450) Controls (n = 83,003)
Age (y), mean (SD) 53.4 (12.7) 58.4 (12.1) 46.1 (12.6)
Sex (females), n (%) 2461 (64.1) 268 (59.6) 48,921 (58.9)
BMI (kg/m2), median (IQR) 26.2 (23.8–29.1) 26.1 (23.9-–29.3) 25.4 (23.1–28.1)
HRV (lnRMSSD, ms), median (IQR) 3.1 (2.6–3.5) 3.0 (2.6-3.5) 3.3 (2.8-3.7)
SBP (mm Hg), median (IQR) 127 (117–140) 130 (120–142) 124 (115–135)
DBP (mm Hg), median (IQR) 74 (68–81) 74 (68–82) 73 (67–80)
MAP (mm Hg), median (IQR) 94 (88–102) 95 (89-–103) 92 (87–99)
PP (mm Hg), median (IQR) 53 (45–62) 54 (46–64.3) 50 (44–58)
High BP, n (%) 1018 (26.6) 135 (30) 15,410 (18.6)
HTN, n (%) 1568 (40.9) 215 (47.8) 21,609 (26.0)
High BP was defined as SBP ≥ 140 mm Hg and/or DBP ≥ 90 mm Hg and HTN as high BP and/or use of antihypertensive medication.
lnRMSSD, logarithm of root mean square of successive differences between normal-to-normal intervals.
C03, and beta-antagonists ATC code C07. The effects of (1)
any antihypertensive medication use, (2) number of antihy-
pertensive medications, and (3) different antihypertensive
medication classes were investigated. Based on evidence of
associations with glaucoma, data analyses were adjusted for
the effects of age, age square, sex, and body mass index
(BMI).37,44–46 BMI was calculated as weight in kilograms
divided by the square of height in meters (kg/m2), from the
baseline assessment.
Data Analysis
Our analyses estimated the association of HRV and BP-
related measurements at baseline with glaucoma at follow-
up, with a median interval of 3.8 years (interquartile range
[IQR], 3.1–4.5). We separately investigated the association of
HTN and antihypertensive medication use with glaucoma.
To test associations, we applied generalized linear mixed
models (GLMMs), in order to adjust for family membership.
First, we combined the three glaucoma classes. Next, we
performed the analyses after excluding possible glaucoma
cases, as there is less certainty in this category. Finally, we
performed the analyses separately for those who were aware
of having glaucoma and for those who were not aware (for
definitions, see the Measurement and Definition of Glau-
coma section). The rationale behind this separation is that
clinical glaucoma cases (aware) differ from glaucoma cases
captured during glaucoma screening (unaware); in the latter
group, NTG dominates,47,48 and, as such, unawareness may
serve as a surrogate for NTG in the current study. We used
GLMM to test the association of HRV, BP-related measure-
ments, HTN, and antihypertensive medications with glau-
coma. A separate model was built for each predictor, except
for the classes of antihypertensive medications, which were
put together in one model. Measurements were analyzed as
continuous traits and as quartiles to accommodate potential
nonlinear effects. In all models, age, age square, sex, and
BMI were used as covariates. In models investigating effects
of BP variables, we additionally investigated interaction by
antihypertensive medication status followed by a stratified
analysis. In models investigating effects of the various anti-
hypertensive medication classes, we additionally adjusted
for the different BP measurements.
In the mixed models, we assumed individuals to be
level-1 observation units clustered by family membership
(level-2). Fitting the logit link function, the odds of glau-
coma for individual i, (i = 1, 2, 3, …, n) in a family
j (j = 1, 2, 3, …, m) was estimated as follows:
log
(
pi j/1 − pi j









where, pij is the probability of glaucoma status, μ is the over-
all mean, β i represents the fixed effects, Xi represents the
prediction variables and covariates (age, age square, sex,
BMI), a is the random effect due to the family relationship,
and e is random error. Data reorganization and cleaning and
descriptive analyses were performed in R 3.5.3 (R Foun-
dation for Statistical Computing, Vienna, Austria) and SPSS
Statistics 23 (IBM, Armonk, NY, USA). GLMM analyses were
executed in ASReml 4.1 (VSNi, Hempstead, UK). Statistical
significance was set at a P value of 0.05 or less.
RESULTS
Of the 110,759 participants invited for the follow-up assess-
ment, 88,584 (80%) had eye-related data. After exclud-
ing 1,743 participants who underwent laser treatment or
surgery for diabetes or retinal detachment or who had age-
related macular degeneration (see Methods section), the
total number of study participants included in the analyses
was 86,841. There were 102 (0.11%) definite glaucoma cases,
348 (0.40%) probable cases, and 3388 (3.90%) possible cases.
Of the possible cases, 1585 (1.82%) were possible by self-
report, and 1803 (2.07%) were possible by complaint. Table 1
shows the characteristics of the study population and the
distribution of HRV and BP data between cases and controls.
We confirmed the well-known relationship between glau-
coma and age; that is, we found a significant positive rela-
tionship between glaucoma and age across all age groups
compared to individuals 55 years old (Supplementary
Table S1).
All Glaucoma Cases Combined
We found a negative relationship between glaucoma and
baseline HRV, represented by RMSSD. The odds ratio (OR) of
glaucoma was 0.95 (95% confidence interval [CI], 0.92–0.99;
P= 0.005) per unit increase in log-transformed RMSSD (with
RMSSD expressed in ms), which means that autonomous
dysfunction (low HRV) is associated with a higher risk
of glaucoma (Fig., part A). Alternatively, most BP-related
measurements, including SBP, PP, high BP, HTN, and the
use of antihypertensive medication, showed a significant
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FIGURE. Association of glaucoma with HRV and BP-related measurements before (A) and after (B) excluding possible glaucoma cases. High
BP was defined as SBP ≥ 140 mm Hg and/or DBP ≥ 90 mm Hg and HTN as high BP and/or use of antihypertensive medication. The GLMM
was adjusted for age, age square, sex, and BMI. The number of anti-HTN medications (combinations) was modeled as a continuous variable.
TABLE 2. Association of Glaucoma with Antihypertensive Medication Use
All Cases Possible Cases Excluded
Antihypertensive Glaucoma Glaucoma
Medication Class Cases/Controls OR (95% CI) P Cases/Controls OR (95% CI) P
Beta-antagonists 403/4613 1.06 (0.94–1.19) 0.319 60/4613 1.06 (0.78–1.42) 0.695
Diuretics 292/2858 1.09 (0.95–1.25) 0.229 41/2858 0.99 (0.69–1.42) 0.982
ACE inhibitors 299/2908 1.35 (1.18–1.55) <0.001 50/2908 1.48 (1.07–2.06) 0.017
Angiotensin II blockers 187/1943 1.16 (0.98–1.37) 0.080 22/1943 0.86 (0.54–1.35) 0.515
Calcium-channel blockers 191/1734 1.19 (1.01–1.40) 0.039 30/1734 1.16 (0.78–1.73) 0.443
Other medication use 25/220 1.29 (0.84–2.00) 0.243 5/220 1.97 (0.79–4.92) 0.142
Models were adjusted for age, age square, sex, and BMI. Other medications included renin inhibitors, alpha-/beta-blockers, alpha blockers,
alpha agonists, antiadrenergics, serotonin antagonists, potassium channel enhancers, and smooth muscle relaxants. Values with statistical
significance are shown in bold.
positive association with glaucoma; see part A of the Figure
for the results of the continuous trait analysis. After stratify-
ing by type of medication, only ACE inhibitors and calcium-
channel blockers were statistically significant (Table 2),
showing a harmful effect. These medication effects did not
change when adjusting for BP measurements (Supplemen-
tary Table S2).
When analyzed in quartiles (Table 3), participants in the
lowest quartile of log-transformed RMSSD demonstrated a
higher odds ratio for glaucoma (OR, 1.15; P = 0.003). For
BP-related measurements, PP was significantly associated
with glaucoma, as participants in the highest quartile of PP
were 1.13 times more likely to have glaucoma (P = 0.015)
compared to those in the second quartile.
Neither continuous nor categorical BP analyses showed
significant interactions by antihypertensive medication
status (data not shown), but, when stratified by antihyper-
tensive medication status, more clearly positive associations
between BP and glaucoma in those not taking antihyperten-
sive medication was observed (Supplementary Table S3).
Table 4 shows the effect of the various risk factors for
participants who were aware of their glaucoma status (defi-
nite, probable, and possible by self report, n = 2035 cases)
versus those who were not (possible by complaint, n =
1803; a NTG surrogate, as described in the Methods section).
The risk of high BP was observed only among participants
who were aware of their glaucoma status. In contrast, HRV
was significantly associated with glaucoma in both groups,
Downloaded from iovs.arvojournals.org on 09/25/2020
Association of Autonomic Dysfunction and Blood Pressure with Glaucoma IOVS | September 2020 | Vol. 61 | No. 11 | Article 25 | 5
TABLE 3. Odds Ratios of Glaucoma for Different Categories of HRV and BP-Related Measurements (Quartiles)
All Cases Possible Cases Excluded
Predictor Glaucoma Cases/Controls OR (95% CI) P Glaucoma Cases/Controls OR (95% CI) P
HRV (lnRMSSD)
≤2.85 1272/19,905 1.15 (1.05–1.27) 0.003 159/19,905 1.07 (0.82–1.41) 0.610
2.86–3.30 946/19,968 1.05 (0.95–1.16) 0.312 113/19,968 1.09 (0.82–1.45) 0.561
3.31–3.77 796/20,124 1.03 (0.93–1.14) 0.603 91/20,124 1.14 (0.85–1.54) 0.384
≥3.78 645/20,267 Reference — 62/20,267 Reference —
SBP (mm Hg)
≤115 805/21,907 0.99 (0.89–1.09) 0.818 70/21,907 0.84 (0.61–1.15) 0.284
116–124 826/20,347 Reference — 94/20,347 Reference —
125–135 965/21,019 1.02 (0.93–1.12) 0.689 131/21,019 1.12 (0.85–1.46) 0.417
≥136 1238/19,696 1.09 (0.99–1.19) 0.091 155/19,696 0.91 (0.70–1.20) 0.515
DBP (mm Hg)
≤67 879/21,456 0.98 (0.89–1.08) 0.450 96/21,456 0.93 (0.71–1.21) 0.575
68–73 1027/22,166 Reference — 128/22,166 Reference —
74–80 916/20,337 0.91 (0.83–1.00) 0.048 97/20,337 0.74 (0.57–0.97) 0.03
≥81 1012/19,010 1.01 (0.92–1.11) 0.810 129/19,010 0.95 (0.74–1.22) 0.681
MAP (mm Hg)
≤87 719/21,191 0.97 (0.88–1.07) 0.660 55/21,191 0.68 (0.50–0.91) 0.008
88–92 774/21,863 Reference — 92/21,863 Reference —
93–99 949/20,023 0.97 (0.88–1.07) 0.528 119/20,023 0.81 (0.62–1.06) 0.118
≥100 1391/19,885 1.01 (0.92–1.11) 0.849 184/19,885 0.78 (0.61–1.00) 0.05
PP (mm Hg)
≤44 842/22,795 1.00 (0.91–1.11) 0.968 84/22,795 0.90 (0.66–1.21) 0.483
45–50 757/18,987 Reference — 88/18,987 Reference —
51–58 890/20,619 1.00 (0.91–1.11) 0.936 108/20,619 0.97 (0.73–1.29) 0.841
≥59 1315/20,568 1.13 (1.02–1.24) 0.015 170/20,568 0.94 (0.72–1.24) 0.674
The GLMM was adjusted for age, age square, sex, and BMI. Values with statistical significance are shown in bold.
TABLE 4. Association of Glaucoma with HRV, BP-Related Measurements, and Antihypertensive Medication Use for Cases Who Were Aware
of Their Glaucoma Status Versus Those Who Were Unaware
Glaucoma Cases Glaucoma Cases
Aware of Their Glaucoma Unaware of Their Glaucoma
Status/Controls (2035/83,003) Status/Controls (1803/83,003)
Variables OR (95% CI) P OR (95% CI) P
HRV
lnRMSSD 0.95 (0.91–0.99) 0.045 0.95 (0.90–1.00) 0.044
BP measurements, per 10 mm Hg
SBP 1.08 (1.04–1.11) <0.001 0.98 (0.95–1.01) 0.173
DBP 1.07 (1.02–1.12) 0.008 0.95 (0.90–1.01) 0.078
MAP 1.10 (1.05–1.14) <0.001 0.96 (0.92–1.01) 0.107
PP 1.09 (1.05–1.13) <0.001 0.99 (0.95–1.03) 0.681
High BP 1.21 (1.09–1.35) <0.001 0.97 (0.86–1.10) 0.659
HTN 1.33 (1.20–1.47) <0.001 1.16 (1.04–1.29) 0.008
Medication use
Any anti-HTN medication use 1.25 (1.11–1.40) <0.001 1.35 (1.19–1.53) <0.001
Number of anti–HTN medications 1.13 (1.06–1.21) <0.001 1.18 (1.10–1.26) <0.001
The GLMM was adjusted for age, age square, sex, and BMI. The number of anti-HTN medications (combinations) was modeled as a
continuous variable.
as was the effect of antihypertensive medication. A simi-
lar pattern was seen in the corresponding quartile analysis
(Table 5).
After Exclusion of Possible Glaucoma Cases
We repeated association testing for HRV, BP, high BP, HTN,
and medication use with glaucoma status after excluding
the possible cases. Although the direction of the effects
remained unchanged, excluding 88% (n = 3388 possible
cases) of the 3838 total glaucoma cases resulted in low
power to detect significant differences between cases and
controls (Fig., part B; Table 3).
DISCUSSION
Our findings show that HRV has a negative relationship
with glaucoma, whereas BP-related measurements, includ-
ing HTN, high BP, and antihypertensive medication use
(especially ACE inhibitors and calcium-channel blockers),
have a positive association with glaucoma prevalence. Our
findings support previous work where lower HRV was
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TABLE 5. Association of Glaucoma with HRV and BP-Related Measurements for Cases Who Were Aware of Their Glaucoma Status Versus
Those Who Were Unaware (Quartiles)
Glaucoma Cases Glaucoma Cases
Aware of Their Glaucoma Unaware of Their Glaucoma
Status/Controls (2035/83,003) Status/Controls (1803/83,003)
Variables (Quartile) OR (95% CI) P OR (95% CI) P
HRV, LnRMSSD (ms)
≤2.85 1.14 (1.00–1.29) 0.043 1.16 (1.01–1.33) 0.031
2.86–3.30 1.02 (0.89–1.17) 0.749 1.09 (0.94–1.25) 0.250
3.31–3.77 1.02 (0.88–1.17) 0.787 1.04 (0.90–1.20) 0.610
≥3.78 Reference — Reference —
BP, mm Hg
SBP
≤115 0.92 (0.79–1.06) 0.262 1.05 (0.91–1.20) 0.515
116–124 Reference — Reference —
125–135 1.08 (0.94–1.23) 0.258 0.96 (0.84–1.11) 0.596
≥136 1.21 (1.06–1.38) 0.003 0.94 (0.82–1.08) 0.412
DBP
≤67 0.92 (0.80–1.05) 0.2 1.04 (0.91–1.19) 0.548
68–73 Reference — Reference —
74–80 0.91 (0.80–1.03) 0.149 0.91 (0.80–1.04) 0.167
≥81 1.07 (0.94–1.20) 0.3 0.93 (0.82–1.07) 0.327
MAP
≤87 0.86 (0.75–0.99) 0.043 1.07 (0.93–1.22) 0.342
88–92 Reference — Reference —
93–99 0.93 (0.81–1.06) 0.271 1.02 (0.89–1.17) 0.779
≥100 1.11 (0.98–1.26) 0.093 0.87 (0.76–1.00) 0.058
PP
≤44 0.90 (0.78–1.04) 0.149 1.11 (0.97–1.28) 0.138
45–50 Reference — Reference —
51–58 1.03 (0.89–1.18) 0.667 0.98 (0.85–1.14) 0.810
≥59 1.18 (1.03–1.34) 0.011 1.07 (0.93–1.24) 0.317
The GLMM was adjusted for age, age square, sex, and BMI. Values with statistical significance are shown in bold.
associated with higher prevalence and faster rates of central
visual field loss in NTG.28,49 Our findings regarding HRV
also agree with reports proposing that autonomic dysfunc-
tion contributes to the pathophysiology of glaucoma. For
example, choroidal parasympathetic innervation increases
choroidal blood flow, whereas sympathetic innervation has
the opposite effect. Given that the choroid contributes to
the prelaminar blood supply of the optic nerve head,50
and predominant sympathetic innervation over-constricts
microvessels nourishing the optic nerve head, the inability
to maintain a constant blood supply may promote occur-
rence of the disease.27,51–53 The results of our NTG surrogate
subanalysis also strengthen previous evidence that auto-
nomic dysregulation plays a role in glaucoma.28,49 HRV was
at least as significant in the unaware group as in the aware
group at a similar sample size.
Our results showed an increasing trend of glaucoma at
high BP. These findings support previous population-based
cross-sectional studies where increases in BP are associated
with increased odds of glaucoma. This was found in the
Rotterdam Eye Study,54 the Beaver Dam Eye Study,31 the Blue
Mountain Eye Study,13 and the Egna–Neumarkt Eye Study.55
Our findings also agree with the Los Angeles Latino Eye
Study with respect to SBP and MAP, but not for DBP (see
next paragraph). Our findings contradict the Barbados Eye
Study in terms of SBP; that study reported an OR for glau-
coma of 0.91 (95% CI, 0.84–1.0) per 10-mm Hg increase in
SBP.32 Our findings are in line with a general practitioner
study from the United Kingdom, where glaucoma was more
common among hypertensive individuals (OR, 1.29; 95%
CI, 1.23–1.36; P < 0.001).56 Furthermore, a meta-analysis of
27 observational studies reported an overall relative risk of
1.16 (95% CI, 1.05–1.28; P< 0.05) of glaucoma among hyper-
tensive individuals.57
In the current study, we did not find a J- or U-shaped
relationship (higher risk at both extremes) between glau-
coma and BP. In the National Health and Nutrition Exami-
nation Survey (NHANES) cross-sectional study, Kim et al.15
reported a U-shaped relationship between SBP and glau-
coma among individuals without antihypertensive medica-
tions, but not among those taking medication. However,
this finding contradicts the notion that overtreatment of
HTN (excessive BP lowering due to antihypertensive medi-
cation) may reduce ocular blood flow, with ischemia as a
consequence.9 Similarly, in the Los Angeles Latino Eye Study
(LALES), the U-shaped relationship came from high SBP
(SBP > 170 mm Hg; OR, 2.1; 95% CI, 1.1–4.0) and low DBP
(DBP ≤ 60; OR, 1.9; 95% CI, 1.1–3.0).12 Possible explana-
tions for the apparent discrepancy between NHANES and
LALES and our study are differences in ethnicity, model
building, and glaucoma definition. The reported propor-
tion of Caucasian ethnicity was 76% and 0% in NHANES15
and LALES,12 respectively, compared to 98.3% in our study.
Furthermore, the final statistical model in LALES12 was
corrected for the effects of IOP, a history of high BP, and use
of antihypertensive medication, whereas the model used in
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NHANES was adjusted for antihypertensive medication but
not for IOP.
We did not adjust for IOP (data not available), and vari-
ables related to BP were studied one at a time. Stratification
of our BP analyses by antihypertensive medication status
clearly confirmed the positive association between BP and
glaucoma in those not taking antihypertensive medication,
but there was no indication of a J- or U-shaped relationship.
Glaucoma was defined based on fundus photographs only
in NHANES and on a combination of fundus photographs
and a visual field test in LALES, whereas our glaucoma defi-
nition was based on a questionnaire-based algorithm. Cases
detected with fundus photography and visual field testing in
a population-based setting tend to have a normal to nearly
normal IOP; that is, NTG is frequently found. The role of low
blood pressure has previously been linked to NTG.58
Self-reported glaucoma is one of the features of the
glaucoma classification algorithm in LifeLines; thus, glau-
coma with elevated intraocular pressure might be more
frequent in this sample. This may explain the nonsignif-
icance of hypotension in our primary analysis. Interest-
ingly, the subgroup of participants who were unaware of
their disease status, our NTG surrogate, did not show a
positive relationship with any of the BP-related traits but
did show an association with antihypertensive medication,
where overtreatment may play a role. The fact that high BP
was only significant in the aware group suggests that either
high BP is mainly associated with glaucoma with elevated
pressures or that ascertainment bias plays a role (those with
high BP are more likely to have their glaucoma detected). A
possible reason why high BP relates to glaucoma could be
the association between blood pressure and IOP.59
Suggested mechanisms that explain how high BP affects
the optic nerve head, with ischemia as a consequence,
include blood vessel size that determines blood flow veloc-
ity to the optic nerve head.9,60 The significant relationship
between high PP and glaucoma may reflect the role of vascu-
lar aging; thickening and deposition of collagen in the arte-
rial walls alters normal blood flow to vital organs, including
the eye.61
There are controversies among studies investigating the
effects of antihypertensive medication on glaucoma. Our
study demonstrated that glaucoma is more prevalent in
hypertensive individuals, and the use of each additional anti-
hypertensive medication was associated with a 16% increase
in the odds of glaucoma. However, when we stratified by
class of antihypertensive medications, only ACE inhibitors
and calcium-channel blockers showed statistically signifi-
cant relationships. These effects were independent of BP,
per se, as shown by additionally adjusting for BP measure-
ments. Our findings agree with previous population-based
work in the United Kingdom, where ACE inhibitors and
calcium-channel blocker medication users were more often
diagnosed with glaucoma (OR, 1.16; 95% CI, 1.09–1.24; OR,
1.34; 95% CI, 1.24–1.44, respectively).56 Similarly, a 6.5-year
follow-up study (Rotterdam Study; median age 71 years;
predominantly Caucasian descent)62 showed an increased
glaucoma incidence (1.8-fold; 95% CI, 1.04–3.2; P = 0.037)
among individuals taking calcium-channel blockers. They
did not find any effect (neither protective nor harmful) for
ACE inhibitors. ACE inhibitors are effective in controlling BP
and are typically used in patients with renal hypertension.63
Thus, the strong association of ACE inhibitors with glaucoma
as observed by us may indicate a role for the kidney in glau-
coma, which is worth exploring in future studies.
In the Barbados Eye Studies32 (mean age 56.9 years;
>90% African descent) with 9-year follow-up, antihyperten-
sive medication did not show a relationship with glaucoma
risk. However, the effects of separate antihypertensive medi-
cation classes were not investigated, as the effect of anti-
hypertensive medication was simply modeled as “yes” or
“no.” In a recent clinical study by Zheng et al.,64 calcium-
channel blocker usage was associated with a 26% increased
risk of glaucoma (P < 0.05), although no dose–response
relationship was observed. In the Thessaloniki Eye Study, all
classes of antihypertensive medications were associated with
more glaucomatous damage among subjects with DBP < 90
mm Hg.65 In the same cohort, when compared to untreated
normal DBP (< 90 mm Hg), a significantly larger cup area
and cup-to-disc ratio were observed in those with the same
DBP secondary to antihypertensive medication.66 One expla-
nation could be that excessive BP lowering in response to
antihypertensive medication use, in eyes with compromised
vessels due to chronic high BP, may result in lower perfu-
sion of blood to retinal ganglion cells, with ischemia as a
consequence.67,68
In contrast, a large prescription-based study from
Denmark69 reported that, except for vasodilators, all classes
of antihypertensive medications were significantly associ-
ated with a later onset of glaucoma. Because the vascular
component is a suggested mechanism involved in glaucoma
development and progression, it seems logical to assume
that all antihypertensive medications could also prevent the
occurrence of glaucoma. The authors defined glaucoma by
the use of any glaucoma medication; given that glaucoma
medications are also prescribed for ocular hypertension,
their outcome measure could be a mixture of glaucoma
and ocular hypertension. This suspicion is supported by
the overall glaucoma prevalence estimate of 4.3% (1996–
2012) among people 40 to 95 years old that was reported
in a Danish paper,69 which is higher than the registry-based
(i.e., based on the International Classification of Diseases,
Tenth Revision) definition of glaucoma (1.4–1.9%)70 and also
higher than the European prevalence estimate of 2.93% (95%
CI) for 2013.37 An alternative explanation could be that,
in the Danish healthcare system, high BP is detected and
treated relatively early, resulting in less damage to the blood
vessels (see below). Similar to the Danish study, a recent
prospective cohort study of glaucoma patients and glau-
coma suspects, the Groningen Longitudinal Glaucoma Study,
reported that the use of ACE inhibitors and angiotensin II
receptor blockers was associated with a lower conversion
rate of glaucoma suspects.71
Clearly, the complex association among glaucoma, high
BP, and antihypertensive drugs is not yet fully under-
stood. By merging the above-mentioned findings, a tenta-
tive hypothesis could be that some antihypertensive drug
classes possess neuroprotective properties, but these effects
are only visible if prescribed in a timely manner.69,71 A high
BP itself promotes glaucoma, and, if BP is treated late and/or
suboptimally, antihypertensive drugs may simply reflect a
history of high BP, which may, in the past, have increased
risk of glaucoma development.
Our study has a number of strengths, but also some limi-
tations. Our findings are based on a much larger sample
size than most previous studies, rendering more power to
precisely estimate effect sizes; however, we need to be aware
of the predictive limitation of the cross-sectional design in
establishing exposure–outcome relationships. Furthermore,
we used GLMM to properly adjust for familial relationships
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that otherwise could have inflated the significance of asso-
ciations of HRV and BP with glaucoma. We used a system-
atic approach for defining glaucoma, but it is likely that not
all possible glaucoma cases are truly affected, which may
result in misclassification errors. Almost all study partici-
pants (98.3%) were Caucasian, so direct comparison with
other multi-ethnic study results may not be possible. There-
fore, the results of this study should be interpreted with
these limitations taken into account.
CONCLUSIONS
In summary, using a large population-based cohort, we
examined the association of HRV, BP, high BP, HTN, and
antihypertensive medication use with glaucoma. Except for
HRV, which showed a negative relationship, all other vari-
ables (BP, high BP, HTN, and antihypertensive medication
use) showed a positive association with glaucoma. Our
results indicate that, in addition to the traditional risk factors
(elevated eye pressure, family history, age, and ethnicity),
low HRV and high BP may play a role in glaucoma patho-
physiology. Further population-based prospective studies
may help to better understand the effect of BP and the role
of autonomic dysregulation in predicting glaucoma. Given
that the relationship of antihypertensive medication with
glaucoma remains controversial even in prospective stud-
ies,32,62 other designs such as randomized clinical trials or
Mendelian randomization studies are needed to investigate
which classes of antihypertensive medications truly have a
causal relationship with glaucoma.72
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